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a b s t r a c t 
Collagen microfiber-based constructs have garnered considerable attention for ligament, tendon, and 
other soft tissue repairs, yet with limited clinical translation due to strength, biocompatibility, scalable 
manufacturing, and other challenges. Crosslinking collagen fibers improves mechanical properties; how- 
ever, questions remain regarding optimal crosslinking chemistries, biocompatibility, biodegradation, long- 
term stability, and potential for biotextile assemble at scale, limiting their clinical usefulness. Here, we as- 
sessed over 50 different crosslinking chemistries on microfluidic wet-extruded collagen microfibers made 
with clinically relevant collagen to optimize collagen fibers as a biotextile yarn for suture or other med- 
ical device manufacture. The endogenous collagen crosslinker, glyoxal, provides extraordinary fiber ulti- 
mate tensile strength near 300MPa, and Young’s modulus of over 3GPa while retaining 50% of the initial 
load-bearing capacity through 6 months as hydrated. Glyoxal crosslinked collagen fibers further proved 
cytocompatible and biocompatible per ISO 10993-based testing, and further elicits a predominantly M2 
macrophage response. Remarkably these strong collagen fibers are amenable to industrial braiding to 
form strong collagen fiber sutures. Collagen microfluidic wet extrusion with glyoxal crosslinking thus 
progress bioengineered, strong, and stable collagen microfibers significantly towards clinical use for po- 
tentially promoting efficient healing compared to existing suture materials. 
Statement of Significance 
Towards improving clinical outcomes for over 1 million ligament and tendon surgeries performed annu- 
ally, we report an advanced microfluidic extrusion process for type I collagen microfiber manufacturing 
for biological suture and other biotextile manufacturing. This manuscript reports the most extensive wet- 
extruded collagen fiber crosslinking compendium published to date, providing a tremendous recourse to 
the field. Collagen fibers made with clinical-grade collagen and crosslinked with glyoxal, exhibit tensile 
strength and stability that surpasses all prior reports. This is the first report demonstrating that glyoxal, a 
native tissue crosslinker, has the extraordinary ability to produce strong, cytocompatible, and biocompat- 
ible collagen microfibers. These collagen microfibers are ideal for advanced research and clinical use as 
surgical suture or other tissue-engineered medical products for sports medicine, orthopedics, and other 
surgical indications. 
© 2021 The Author(s). Published by Elsevier Ltd on behalf of Acta Materialia Inc. 
This is an open access article under the CC BY-NC-ND license 
( http://creativecommons.org/licenses/by-nc-nd/4.0/ ) 
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1. Introduction 
Regarding ligament and tendon repairs for the extremities, in 
the US, around 80 0,0 0 0 shoulder repairs, 30 0,0 0 0 foot and an- 
kle repairs, and 20 0,0 0 0 knee surgical soft tissue repairs are per- 
formed annually [1–4] , all involving sutures. Surgical interventions 
to augment, repair, or reconstruct tendons and ligaments include 
autografts, allografts, and synthetic materials as sutures, braces, 
or grafts for soft tissue closure or joining [5,6] , each with clini- 
cal limitations. Allografts can be slow to integrate, inflammatory, 
and may delay healing [4,7,8] . Synthetic grafts or sutures (or “inter- 
nal braces”) elicit a foreign body immune response and can break 
down into acidic byproducts damaging surrounding tissue [9–11] . 
Synthetic sutures often do not match the mechanical or material 
properties of tendons or ligaments [12] , which may lead to the 
generation of stress risers and the creation of a debilitating non- 
isometry if used in a joint space. Autografting extends surgery time 
and associated trauma (e.g., blood loss, risk of infection) due to 
the need for a second procedure to recover the autologous tissue 
[3,13] . Joint reconstruction with autografting or allografting further 
results in a higher incidence and severity of premature osteoarthri- 
tis, affecting the patients’ quality of life [3,14–;16] . 
The opportunity to improve clinical outcomes from current con- 
nective tissue reconstruction strategies has led to the emergence of 
innovative tissue engineering approaches. These approaches aim to 
develop biocompatible materials that can remodel in vivo and sub- 
sequently be biologically integrated by in situ tissue remodeling, 
thus regenerating typical anatomical structure with restored me- 
chanical strength [17,18] . 
Structural and biomechanical functionality in tendons and liga- 
ments is attributed primarily to the presence of dense, aligned fib- 
rillar type I collagen [2 , 4 , 19 , 20] . Therefore, several effort s in gen- 
erating biomaterials to support connective tissue repair have in- 
corporated collagen [3 , 21–23] . Type I collagen in the form of a 
lyophilized sponge was successful in early-stage testing for ACL re- 
pair in a porcine model [24] , where collagen proved a beneficial 
porous regenerative matrix [25–28] . However, the need for an open 
surgical procedure and the inability for the mechanically deficient 
collagen sponge to restore initial mechanical strength has led to 
exploring alternatives for regenerative rehabilitation of ligament, 
tendon, and other soft tissue repairs. 
Collagen-based biomaterials have garnered considerable atten- 
tion in numerous other applications such as sutures for wound clo- 
sure, hemostasis, hernia repair, repair of bone and cartilage defects, 
and treatment of burns [29–31] . Sutures are integral to efficient 
wound healing. However, there is still an unmet need in additive 
manufacturing for a biological and strong suture. Collagen, with its 
vital role in wound healing [32] , may address such an ideal. Histor- 
ically for collagen-based sutures, catgut resorbable sutures (plain 
or chromic) have been used in wound healing [33–35] . Tissue re- 
activity, rapid loss in tensile strength, and unpredictable resorption 
rates have restricted chromium crosslinked catgut suture applica- 
tions [36] . Collagen-coated synthetic suture fibers (e.g., Collagen- 
Coated FiberWire®) are available, yet without claims for enhancing 
or bioactivity. 
Type I collagen can be additively manufactured by extrusion 
into fibers [37 , 38] which exhibit an increase in mechanical strength 
when crosslinked [39–41] . However, most crosslinkers are cytotoxic 
and use chemicals foreign and toxic to the body. Furthermore, prior 
work on collagen wet-extrusion uses collagen from sources not ex- 
tracted under current good manufacturing practices (GMP) condi- 
tions and thus not suited for medical device manufacturing, com- 
plicating these studies’ clinical relevance [39 , 40 , 42–45] . 
This study develops a high output microfluidic wet-extrusion 
system to produce consistent and scalable microfibers of clinically 
relevant type I collagen as filaments and thin ribbon-like struc- 
tures. We optimized fiber production techniques, tested over 50 
different crosslinking formulations, and performed rigorous me- 
chanical and biochemical tests to optimize fundamental fiber prop- 
erties specifically for biomedical use. These collagen fibers have 
potential applications in tendon and ligament repair, wound clo- 
sure, and other indications where an advanced collagen-suture- 
based biomaterial may be beneficial across the fields of surgery in 
medicine. 
2. Materials and methods 
2.1. Collagen preparation and fiber production 
2% (w/v) clinical grade lyophilized telocollagen (Telo) or ate- 
locollagen (Atelo) was used fromCollagen Solutions(CA) or as 
research-grade methacrylated collagen (Advanced BioMatrix, CA) 
was used in these studies. Collagn was dissolved in 0.05 M acetic 
acid or 0.01M hydrochloric acid overnight by agitation. Acidi- 
fied collagen was then pumped through the center of a coax- 
ially arranged set of needles (inner diameter of 0.4mm) at a 
flow rate of 0.06ml/min (setup shown in supplementary Fig. 
S1). A neutralizing alkaline formation phosphate buffer contain- 
ing salts (at pH 8) (Sodium chloride, Sodium Phosphate Dibasic, 
Sodium Phosphate Monobasic, and N-Tris(hydroxymethyl)methyl- 
2-aminoethanesulfonic acid) and PEG (polyethylene glycol) were 
pumped through the outer portion of the coaxial needle and into 
a formation tube of length 610mm. The collagen solution emerged 
into the center of the formation tube. The formation buffer ran at 
a volumetric flow rate ten times higher than the collagen, which 
caused the protein extension and alignment, imparting mechan- 
ical strength to the resulting fiber. The fiber became more solid 
as it passed through the formation tube (dwell time of up to 1.5 
minutes) before entering a bath of 20% aqueous ethanol. In ad- 
dition to dehydrating the fiber, this bath helped remove resid- 
ual formation buffer, thus contributing to improved strength and 
stability of the resultant collagen microfiber. After dehydration, 
the microfiber was collected on a two-bar device or the solid 
spool. Collected microfibers were air-dried for a half hour and 
subsequently crosslinked under different experimental conditions. 
Chemical reagents used during extrusion and crosslinking are in- 
cluded in Supplementary Table S1 . 
2.2. Microfiber crosslinking 
In situ crosslinking (chemical or enzymatic) for the groups 
shown in Table 1 was performed by dissolving the determined 
amount of the crosslinker in acidified collagen mixture for the time 
stated in Table 1 . Microfibers from in situ crosslinked collagen were 
then extruded onto a two-bar device and kept taut, as shown in 
Fig. S2. 
Post-extrusion chemical crosslinking, untreated or in situ 
crosslinked, and taut collagen microfibers extruded on the two-bar 
device or the solid spools were air-dried a half hour and then sub- 
merged into a solution of crosslinker in 70% ethanol solution and 
then placed on a rocker at low speed. Post crosslinking, microfibers 
were stored in a desiccator. Previous reports used to obtain infor- 
mation on various chemical crosslinkers, their concentrations, and 
crosslinking durations are provided in Table 1 . 
The DHT for crosslinking microfibers involved dehydrating re- 
laxed extruded microfibers at 110 °C and under vacuum for 1, 3, 
and 5 days with or without additional glyoxal crosslinking as de- 
scribed above. 
For UVR mediated crosslinking, methacrylated collagen was 
used for extrusion. The extruded microfibers were exposed to a 
365nm emitting UV light source for 20 minutes. These microfibers 
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Table 1 
Collagen Microfiber Crosslinking Strength Comparison. Conditions highlighted in red were selected for further characterization post crosslinking optimization. 
Crosslinker Collagen Starting 
Material 
In Situ Post Crosslinker 
Concentration 
Time [hours] Mean UTS [MPa] ±
S.E.M. 
References 
Untreated Telocollagen 6.1 ± 1.2 
Untreated Atelocollagen 8.8 ± 1.7 
Choline Bitartarate Telocollagen Y 1mM 0.5 CBD a [46] 
Choline Bitartarate Telocollagen Y 100mM 0.5 CBD a 
Dehydrothermal 
treatment (DHT) 
Telocollagen Y 72 16.0 ± 1.2 ∗ [47,48] 
DHT Telocollagen Y 120 13.1 ± 0.7 
DHT Telocollagen Y 24 4.7 ± 0.4 
DHT/Glyoxal Telocollagen Y 10mM 120/24 27.2 ± 2.8 ∗ [39,40] 
DHT/Glyoxal Telocollagen Y 10mM 24/24 22.0 ± 3.0 
DL-Glyceraldehyde Atelocollagen Y 25mM 72 128.0 ± 11.8 ∗
DL-Glyceraldehyde Telocollagen Y 25mM 24 70.5 ± 6.0 
DL-Glyceraldehyde Atelocollagen Y 25mM 24 50.7 ± 3.3 
DL-Glyceraldehyde Telocollagen Y 25mM 72 40.3 ± 1.8 
DL-Glyceraldehyde Telocollagen Y 10mM 24 37.1 ± 2.2 
DL-Glyceraldehyde Telocollagen Y 5mM 24 35.3 ± 2.1 
DL-Glyceraldehyde Telocollagen Y 50mM 24 31.1 ± 1.2 
DL-Glyceraldehyde Telocollagen Y 250mM 5 27.3 ± 1.6 
DL-Glyceraldehyde Telocollagen Y 500mM 24 60.4 ± 1.5 
DL-Glyceraldehyde Telocollagen Y 250mM 5 60.2 ± 4.5 
DL-Glyceraldehyde Telocollagen Y 500mM 5 28.6 ± 1.5 
EDC Telocollagen Y 0.25mM 24 16.6 ± 1.5 ∗ [42] 
EDC Telocollagen Y 0.25mM 4 6.5 ± 0.5 
EDC Telocollagen Y 0.25mM 1 2.8 ± 0.1 
EDC/NHS Telocollagen Y 0.25mM/0.125mM 24 30.2 ± 1.0 ∗ [49,50] 
EGCG Telocollagen Y 200[μM] 2 2.2 ± 0.1 ∗ [51] 
EGCG Telocollagen Y 1mM 2 1.1 ± 0.1 
Glyoxal Telocollagen Y 10mM 72 121.2 ± 7.4 ∗ [52] 
Glyoxal Telocollagen Y 10mM 24 109.0 ± 7.4 
Glyoxal Telocollagen Y 100mM 72 76.2 ± 8.0 
Glyoxal Atelocollagen Y 10mM 24 62.1 ± 4.9 
Glyoxal Telocollagen Y 1mM 24 49.4 ± 1.6 
Glyoxal Telocollagen Y 5mM 24 45.9 ± 4.1 
Glyoxal Atelocollagen Y 10mM 72 28.6 ± 2.8 
Glyoxal Telocollagen Y 500mM 72 86.9 ± 5.5 
Glyoxal Telocollagen Y 0.5mM 24 48.3 ± 2.2 
Glyoxal Telocollagen Y 10mM 5 5.1 ± 0.2 
Glyoxal Telocollagen Y 0.5mM 5 2.3 ± 0.4 
Glyoxal/DHT Telocollagen Y 10mM 24/24 24.2 ± 1.3 




Telocollagen Y Y 0.1mg/ml 10mM 72 6.2 ± 1.0 
L-Lysine/Glyoxal Telocollagen Y Y 10mM/10mM 2/24 96.9 ± 4.6 ∗
L-Lysine/Glyoxal Telocollagen Y Y 5mM/10mM 2/24 32.2 ± 1.5 
Methyl Glyoxal Telocollagen Y 10mM 24 42.3 ± 4.1 
NDGA Telocollagen Y 0.01gm/ml 24 47.9 ± 4.2 [39,53] 
O-Dextran Telocollagen Y 20% [w/v] 24 4.4 ± 0.1 
Procyanidin Telocollagen Y 2.5mg/ml 24 19.3 ± 1.5 
Procyanidin Telocollagen Y 5mg/ml 24 13.3 ± 0.9 
D-Sorbitol/Glyoxal Telocollagen Y Y 330mM/10mM 72 22.2 ± 5.2 
D-Sorbitol Telocollagen Y 200mM 72 14.4 ± 0.7 ∗
D-Sorbitol Telocollagen Y 100mM 72 5.8 ± 0.4 
D-Sorbitol Telocollagen Y 200mM 5 1.9 ± 0.2 
UVR Methacrylated Y 0.3 1.9 ± 0.2 
UVR/Glyoxal Methacrylated Y 10mM 0.3/24 86.6 ± 10.1 ∗
a CBD: Could not be determined; 
∗ Significantly High UTS for the crosslinker group (p < 0.01) 
were then placed in a desiccator or further crosslinked with 10mM 
glyoxal in 70% aqueous ethanol. 
Optimization in manufacturing techniques led to a change in 
the microfiber collection method during extrusion. The two-bar 
setup was replaced by a solid spool (Supplementary Fig. S2) with 
closely spaced grooves, and microfibers were collected directly 
onto these grooves while maintaining tautness. In comparison to 
the two-bar device, collection onto spools helped scale up our 
microfiber production significantly. Spools of collagen microfibers 
were crosslinked using various chemicals in 70% aqueous ethanol 
in acrylic tubes placed on rollers and rotated at 1 rpm to ensure 
uniform microfiber crosslinking. 
2.3. Mechanical testing of collagen microfibers 
To meet the demands of rigorous mechanical testing relevant 
to collagen microfibers’ performance in vivo , we developed a high- 
throughput method of wet-tensile-testing microfiber samples (Sup- 
plementary Fig. S3). This method is described in detail in supple- 
mentary method S1.1. 
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2.4. Scanning electron microscopy (SEM) 
SEM imaging was used to obtain cross-sectional and longitu- 
dinal microstructural signatures of our untreated/non-chemically 
cross-linked and cross-linked extruded microfibers. SEM imaging 
was performed at Embody, Inc. (Norfolk, VA) using a Zeiss Evo 10 
microscope (Zeiss) with a 10kV beam intensity. For cross-sections, 
microfiber bundles were soaked in DPBS for 30 minutes, dried for 
an hour on SEM stubs, sputter-coated, and imaged. 
2.5. Degree of crosslinking 
We used ninhydrin assay to evaluate the number of free amino 
groups in glyoxal and DL-Glyceraldehyde crosslinked microfibers 
following the manufacturer’s protocol (details in Supplemental 
Methods S1.3). 
2.6. Differential scanning calorimetry (DSC) and Fourier-transform 
infrared (FTIR) spectroscopy of microfibers 
DSC was performed using a Differential Scanning Calorimeter 
(DSC2500, TA Instruments, DE), and FTIR spectroscopy was per- 
formed on Platinum ATR (Brucker, Billercia, MA) at Old Dominion 
University (ODU) (Norfolk, VA). FTIR spectra were obtained from 
40 0cm −1 to 40 0 0cm −1 at a resolution of 4cm −1 and averaged over 
32 scans. Untreated and crosslinked microfibers were compared to 
the starting material by assessing shifts in peaks with the Essential 
FTIR bioinformatics software (Operant, Madison, WI). 
2.7. Cell attachment, cytocompatibility, viability, and cytotoxicity 
assays 
Crosslinked collagen microfibers were sealed inside Tyvek 
pouches with a STERRAD chemical indicator (4MD Medical Solu- 
tions, Lakewood, NJ) and sent for E-beam sterilization (Steri-Tek, 
Fremont, CA) using a 20KGy + /-2KGy target dose. 
Sterilized glyoxal and DL-Glyceraldehyde crosslinked mi- 
crofibers were hydrated in tenocyte growth media (ZenBio, NC) 
for 30 minutes and placed in 24-well plates pre-coated with Poly 
(2-hydroxyethyl methacrylate) (pHEMA) (Sigma Aldrich) to inhibit 
cell binding to the culture vessel. Human tenocytes (ZenBio, NC) 
(in 100μl tenocyte growth media) were seeded at 2.5 × 10 4 on 
sterilized microfibers in triplicates. After seeding, cells were al- 
lowed to attach for 1 hour before an additional 500μl of tenocyte 
growth media was added. After 12 days in culture, tenocytes at- 
tached to collagen microfibers were stained with live cellular stain, 
CellTracker TM Green CMFDA (5-chloromethylfluorescein diacetate) 
(Thermo Fisher Scientific) following the manufacturer’s protocol. 
Samples were then fixed using 4% paraformaldehyde and subse- 
quently stained with a nuclear stain, DAPI (Thermo Fisher Scien- 
tific), to visualize attached tenocytes on microfibers using a confo- 
cal microscope (Zeiss Axio Observer Z1, Zeiss) at Eastern Virginia 
Medical School, Norfolk, VA. 
Cytotoxicity from extruded microfibers effects on human 
tenocytes was assessed using the CyQuant Lactate Dehydroge- 
nase (LDH) cytotoxicity assay kit (Invitrogen) and MTT (3-(4,5- 
dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide) assay kit 
(Sigma Aldrich) per manufacturer’s protocol. After optimizing seed- 
ing density for the assay, 7 × 10 3 tenocytes were plated on each 
well of 48-well plates and allowed to grow for 24 hours in teno- 
cyte growth media in a humidified incubator maintained at 37 °C 
and 5% CO 2 . Sterilized microfiber bundles were rinsed for 10 min- 
utes in cell culture media and placed on tenocytes in each well. 
Tenocytes grown on plastic (cells only) were used as positive 
(for cell survival or viability) controls. Zinc dibutyldithiocarbamate 
(ZDBC) film and 10mM glyoxal were used as negative (for cell sur- 
vival or viability) controls. The effects of Ethicon vicryl suture were 
also assessed as a control in this experiment as it was used to hold 
our extruded microfiber bundles together in early testing. Wells 
seeded with tenocytes and controls as described in the manufac- 
turer’s protocol. Samples were incubated for seven days before as- 
sessing the release of LDH in the media. Cytotoxicity per the LDH 
assay was calculated following the manufacturer’s protocol, with 
cell survival percentage calculated as 100 - % cytotoxicity. Cell via- 
bility using MTT assay was calculated following the manufacturer’s 
protocol. 
The health and viability of live tenocytes growing with 
our extruded microfibers were additionally assessed using the 
AlamarBlue TM assay (Bio-Rad, Hercules, CA) as per the manufac- 
turer’s protocol. 
2.8. Subcutaneous implants of crosslinked microfiber bundles in rats 
According to an Institutional Animal Care and Use Commit- 
tee (IACUC) approved protocol, all surgical procedures were con- 
ducted at Old Dominion University, Norfolk, VA. Per ISO 10993- 
6, n = 6 crosslinked collagen microfiber bundles (prepared and 
sterilized as described in Section 4.8) and commercially avail- 
able collagen-coated polyester, and ultrahigh molecular weight 
polyethylene (UHMWPE) suture (FiberWire TM from Arthrex, FL, in 
date from www.esuture.com ) were implanted subcutaneously in 
female Sprague Dawley rats. Rats were anesthetized with isoflu- 
rane inhalation. Incisions were made dorsally in the flank area, and 
a hemostat was used to create a pocket for implants. After four 
weeks, the rats were humanely euthanized for tissue collection. 
2.9. Histology 
Harvested microfiber explants at four weeks were fixed in 4% 
paraformaldehyde (Alfa Aesar). The samples were sectioned to ob- 
tain 5 μm thickness, and immunolabeling was performed on se- 
rial sections to detect the presence of CCR7 (M1) and CD163 (M2) 
macrophage phenotypes in native tissues surrounding our implants 
using standard protocols provided by antibody manufacturers. The 
immunolabeled slides were examined and imaged using an in- 
verted light microscope (Axio Vert.A1 Model, Zeiss). Fluorescence 
images were acquired for the test and control slides (data not 
shown) under the same exposure conditions. The images for the 
test samples were evaluated. Quantitative analysis was performed 
to obtain the number of cells expressing M1 only, M2 only, M1 and 
M2, or no M1/M2 phenotype. Here 4-5 areas per image (3 images 
were analyzed per test sample) of approximately 20-30μm at the 
interface of the implants and native tissue (2-3 cell layers) were 
analyzed using a high-power microscope field (40x magnification). 
The total number of cells was determined by counting DAPI stained 
nuclei. The number of cells labeled positively for each marker(s) 
was also counted. The proportion of cells labeled with the specific 
marker(s) was determined as a percentage of the total number of 
cells in that region. 
2.10. Long term stability testing of the hydrated crosslinked collagen 
microfibers 
Crosslinked microfibers were de-spooled under tension onto 
cartridges. Six sterilized (see Section 2.7 ) cartridges were hydrated 
and mechanically tested (Section 4.3) to obtain mechanical prop- 
erties of the microfibers before incubating the remainder of the 
sterilized cartridges in a petri dish containing Eagle’s Minimum Es- 
sential Medium (EMEM) (ATCC, VA) supplemented with 1% Gib- 
coTM Antibiotic-Antimycotic (ABAM) (Thermo Fisher Scientific) in 
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Fig. 1. Mechanical properties of representative crosslinked microfibers from 22 selected groups from Table 1 . (A) UTS, (B) Modulus, and (C) % Strain at Failure of a single 
microfiber reveal strength tunable to meet or exceed human Anterior Cruciate Ligament (ACL) (black line), human Achilles Tendon (AT) (teal line) and human dermis (brown 
line) by changing crosslinking scenarios. Data represent four or more identical replicates, and error bars indicate S.E.M. (For interpretation of the references to color in this 
figure legend, the reader is referred to the web version of this article.) 
an incubator maintained at 37 °C and 5% CO 2 . Throughout the ex- 
periment, cartridges were fully submerged and hydrated in sterile 
media. Six soaked cartridges were removed at 1 week, 1 month, 
3 months, and 6 months to perform MTS testing. Simultaneously, 
microfiber diameters were measured (as described in Section 4.3) 
to determine the microfibers’ swelling over time. 
2.11. Statistical analyses 
Two-way ANOVA followed by the posthoc Tukey’s Multiple 
Comparison Test and unpaired two-tail t-test assessed tensile prop- 
erty differences for different crosslinker groups in Table 1 and 
Figs. 1 and 3 . A priori, p values < 0.05 were defined as significant. 
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All tests were performed using GraphPad Prism 7, and all parame- 
ters are expressed as Mean ± Standard Error of the Mean (S.E.M.). 
3. Results 
3.1. Bio-manufacturing and mechanical properties 
A microfluidic extrusion setup with coaxial flow consistently 
generated collagen microfibers ( Supplementary Fig. S1 ) for subse- 
quent testing (Section 4.3). This approach yielded continuous mi- 
crofiber production without defects for subsequent crosslinking. 
To strengthen and stabilize the collagen microfibers, we 
screened a wide range of conventional, new, and combination 
crosslinking conditions. Table 1 shows a summary of crosslink- 
ers and the mean average hydrated Ultimate Tensile Strength 
(UTS) of 51 types of crosslinked microfibers compared to the 
untreated/non-chemically crosslinked microfibers using the testing 
method described in Section 4.3. Although the untreated group 
was not chemically crosslinked, air-drying the fibers after extru- 
sion can result in covalent linking between triple helices (between 
alpha chains); a dehydrothermal crosslinking that occurs at room 
temperature. The data in Table 1 showed that different crosslink- 
ers/crosslinking protocols (crosslinking in situ or post extrusion, 
range of crosslinker concentrations, and crosslinking time) affected 
the UTS of the microfibers. The crosslinking condition with signifi- 
cantly high mean UTS amongst all the chemistries tested with that 
crosslinker is starred (p < 0.01) in Table 1 . 
Crosslinking procedures post extrusion with chemicals such as 
glyoxal (10mM and 72 hours post extrusion, 121.2 ± 7 MPa) and 
DL-Glyceraldehyde (25mM and 72 hours post extrusion, 128 ±
12 MPa) resulted in microfibers with UTS nearly 20-fold higher 
than the untreated/non-chemically crosslinked microfiber (6.1 ± 1 
MPa). Notably, crosslinking using EDC and EDC/NHS on microflu- 
idic microfibers using our extrusion setup yielded UTS values of 
16.6 ± 2 MPa and 30.2 ± 1 MPa, respectively, which are sig- 
nificantly lower than the glyoxal and DL-Glyceraldehyde. In situ 
(crosslinked mixed with collagen during wet extrusion) crosslink- 
ing using chemical crosslinkers such as choline bitartrate (1mM 
or 100mM), EGCG (200μM or 1mM), and D-sorbitol (200mM) re- 
sulted in a significant decrease (p < 0.01) in UTS compared to un- 
treated microfiber. Physical crosslinking techniques such as dehy- 
drothermal treatment (DHT) (3 days, 16.2 ± 1 MPa) post extrusion 
also yielded microfibers stronger than the untreated microfiber. 
Still, they were weaker than the chemical crosslinking groups us- 
ing glyoxal and DL-Glyceraldehyde described above. Ultraviolet Ra- 
diation (UVR) treatment (1.9 ± 0.2 MPa) of methacrylated collagen 
microfibers post extrusion also yielded fibers significantly weaker 
than untreated telocollagen microfibers (p < 0.01). 
With glyoxal crosslinking producing the highest UTS, we fur- 
ther tested glyoxal crosslinking in situ (alone or with L-Lysine or 
D-Sorbitol) and physically crosslinked fibers (DHT and UVR) with 
10mM glyoxal for various time points to explore any effects on 
strength change. Adding crosslinking with glyoxal to these meth- 
ods increased the UTS of all these groups, with the most significant 
increase (p < 0.01) observed for L-Lysine (10mM, 2hours)/Glyoxal 
(10mM, 24 hours) (96.9 ± 5 MPa) and UVR (0.3 hours)/glyoxal 
(10mM, 24hours) (86.6 ± 10 MPa) groups. However, none of these 
groups were as strong as crosslinking with glyoxal alone. 
We compared mechanical properties ( Fig. 1 ) from crosslinker 
groups tested in Table 1 to values reported for human ACL [54 , 55] , 
Achilles tendon [56] , and dermis [57] . Results revealed that the av- 
erage (mean) wet UTS of collagen microfibers for select crosslink- 
ing groups, notably, 10 mM glyoxal with or without 10mM L-Lysine 
in situ, and 25mM DL-Glyceraldehyde are equal to or greater than 
reported UTS of human ACL, AT, and dermis. 
Fig. 2. Telo GLY microfiber(s) depicting ultrastructural features. Light microscopy 
image of a single dry extruded crosslinked microfiber (A), SEM images of a dry mi- 
crofiber (B) and (C), a cross-section of bundled microfibers soaked for 30 minutes 
in DPBS (D) reveals structural details with consistent, uniform, and ribbon-like mi- 
crofibers produced. Arrows indicate microfiber crevice and ridges. Scale bars are (A) 
50μm, (B) 10μm, (C) 3μm and (D) 20 μm. 
Four crosslinking conditions selected from the initial screen 
( Table 1 bolded and Fig. 1 ) were chosen for further investigation, 
chosen for overall optimal biomechanical performance, processing 
time, complexity, and cost. The selected crosslinking groups are 
(1) telocollagen crosslinked with 10mM glyoxal for 72 hours ( Telo 
GLY ), (2) telocollagen crosslinked with 25mM DL-Glyceraldehyde 
for 24hours ( Telo DLG ), (3) atelocollagen crosslinked with 10mM 
glyoxal for 24 hours ( Atelo GLY ), (4) atelocollagen crosslinked with 
25mM DL-Glyceraldehyde for 72 hours ( Atelo DLG ) and (5) telocol- 
lagen crosslinked with 0.25mM EDC for 24 hours (Telo EDC) and 
compared to untreated microfibers and dry Telo GLY fibers. EDC 
is included for comparison as it is commonly used in the collagen 
TEMP field [42 , 49 , 58] . 
3.2. Characterization of microfiber ultra-structure using a light 
microscope and SEM imaging 
With basic crosslinking formulations optimized for future anal- 
ysis, a high draw collection apparatus to draw the collagen fibers 
onto a flat solid spool (Supplementary Fig. S2 ) was used to 
maximize subsequent studies’ fiber material properties. Collecting 
crosslinked fibers on the grooved drum produced thin, ribbon- 
like microfibers ( Fig. 2 ). Light microscopy imaging ( Fig. 2 A ) and 
SEM imaging ( Fig. 2 B ) confirmed the dry microfiber’s homoge- 
nous width along the longitudinal axis. Fig. 2 B and high magnifica- 
tion SEM ( Fig. 2 C ) imaging of longitudinal section revealed parallel 
alignment of ridges and crevices within the dry microfiber. Fig. 2 D 
highlights cross-sectional features of hydrated extruded crosslinked 
microfiber bundle using SEM. These images showed ultrastruc- 
tural features of an external smooth surface with apparent fibrous 
sub-fiber structure, demonstrating that extruded crosslinked mi- 
crofibers are consistent, thin, and ribbon-like. 
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Fig. 3. Changes in ribbon-like collagen fibers’ mechanical properties from select crosslinking groups (see text) post-optimization of microfiber collection onto a flat solid 
spool. There was a significant increase in the tensile properties of all the extruded microfibers. The untreated microfiber group demonstrated the greatest change in mean 
UTS and modulus compared to other crosslinker groups. Values of width (A) and (B) thickness of the microfibers were used to evaluate (C) UTS and (D) Modulus of 
crosslinked microfibers soaked for 30 minutes in DPBS. (E) and (F) demonstrate a significant change in mechanical properties compared to the data reported in Fig. 1 . 
Results are shown as Mean ± S.E.M. and are representative of 3 replicates from 2 or more separate experiments. ( ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.005 and ∗∗∗∗p < 0.0 0 01). 
Optimization of crosslinking chemistry and collection methods 
ultimately led to significant differences in mechanical properties 
( Fig. 3 ). The width and thickness of hydrated microfibers ( Fig. 3 A 
and B ) measured from representative images such as those shown 
in Fig. 2 A-C were used to calculate the improved UTS and modu- 
lus ( Fig. 3 C and D ). When compared to the wet untreated (34.1 ±
2 μm) microfibers, wet Atelo GLY (39.2 ± 1 μm) and Telo EDC (46.4 
± 2 μm) microfibers showed a significantly higher width (p < 0.05). 
Wet Atelo GLY microfibers were also significantly thicker (11.9 ±
0.5 μm) than the untreated microfibers (9.2 ± 0.5 μm) (p < 0.01). 
Fiber thickness of Telo GLY (11.1 ± 0.5 μm), Telo DLG (8.6 ± 0.2 
μm) and Atelo DLG (10.9 ± 0.4 μm), as well as widths of Telo GLY 
(36.1 ± 0.7 μm), Telo DLG (35.4 ± 0.8 μm) and Atelo DLG (31.1 
± 1 μm) hydrated microfibers were similar to that for the un- 
treated fiber. The most significant change in UTS was observed for 
untreated fibers; mean UTS and modulus increased from 6.1 ± 1 
MPa and 119.8 ± 23 MPa to 35.8 ± 3 MPa and 701 ± 53 MPa. Mi- 
crofibers from groups such as Telo GLY (121 ± 7 MPa UTS and 1103 
± 63 MPa modulus to 299 ± 15 MPa and 3431 ± 86 MPa respec- 
tively) and Atelo DLG (128 MPa UTS and 1734 ± 79 MPa modulus 
to 231 ± 18 MPa and 3408 ± 185 MPa respectively) demonstrated 
at least a 2-fold increase in mean UTS and modulus ( Fig. 3 E and 
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Fig. 4. Degree of crosslinking and biophysical characterization of crosslinked microfiber groups. (A) The crosslinking degree of extruded microfibers was compared to the 
untreated microfiber (0%) using the ninhydrin assay determines free amino groups in the microfiber. Telo GLY and Atelo DLG groups demonstrated maximum crosslinking 
degrees compared to Telo DLG and Atelo GLY. (B) Thermal denaturation scans of extruded microfibers compared to the untreated microfibers show a small increase in 
melting temperatures. The melting temperature of human AT (solid vertical line) is significantly lower than the extruded microfibers’ average melting temperature (dotted 
line). ATR-FTIR spectra (C) of untreated and crosslinked microfibers compared to Type I collagen starting material (freeze-dried, unprocessed). Data in (A) is shown as Mean 
± S.E.M. and represents three replicates from two separate experiments. ( ∗p < 0.05). 
3.3. Degree of crosslinking, biochemical and biophysical 
characterization of the crosslinked microfibers 
A ninhydrin assay was used to assess the crosslinking degree 
( Fig. 4 A) biochemically. Telo GLY (86 ± 1 %) and Atelo DLG (82 
± 3 %) microfibers demonstrated a significantly higher degree of 
crosslinking compared to Atelo GLY (68 ± 4 %) and Telo DLG (59 
± 6 %), highlighting that higher time of crosslinking improved 
crosslinking efficiency. SDS-PAGE subsequently assessed the pri- 
mary and secondary protein structure of the extruded collagen 
microfibers. Analysis of the acidified starting material confirmed 
primary collagen alpha, beta, and gamma chains present in the 
crosslinked collagen fibers ( SupplementaryFig. S4A) . However, due 
to the microfibers’ inability to be dissolved in 0.05M acetic acid, 
collagen was not present in the microfiber acid extracts. To fur- 
ther explore this, we attempted to dissolve the microfibers (un- 
treated and crosslinked) in a variety of solvents at room tem- 
perature (RT) as well as 37 °C for 24-48hours with stirring. We 
tested 10mM HCl, 100mM HCl, 0.5M Acetic acid and 1M Acetic 
Acid. While the untreated fibers readily dissolved in 100mM HCl, 
0.5M Acetic acid, and 1M Acetic Acid both at RT and 37 °C within 
24hours, the crosslinked fibers dissolved minimally ( < 2%) only at 
37 °C after 48hours. SDS-PAGE analysis ( SupplementaryFig. S4B ) 
confirmed the presence of α, β , and γ regions for the untreated 
hydrolyzed material and very faint bands of α regions compared 
to the starting material. 
Since our crosslinked collagen microfibers were resistant to acid 
hydrolysis, we performed limited pepsin digestion and collagenase 
digestion to explore if our extruded microfibers retained partial or 
complete triple-helical structure characteristic of type I collagen in 
connective tissues [19 , 59–61] . Supplementary Fig. S5 demonstrates 
that the un-crosslinked and the Telo GLY fibers were completely 
digested using collagenase in vitro . SupplementaryFig. S6 demon- 
strates that the untreated Telo fibers were partially digested with 
pepsin at 2 hours with visible alpha bands on SDS-PAGE. However, 
the Telo GLY fibers were not digested in the presence of pepsin, 
as seen by the lack of bands on the SDS-PAGE gel in Supplemen- 
tary Fig. S6 . These results suggest that our extruded microfibers 
retained a significant part of the native triple-helical structure post 
glyoxal crosslinking. 
Biophysical characterization using differential scanning 
calorimetry (DSC) measurements on extruded microfibers re- 
vealed an insignificant increase in melting temperatures between 
the untreated and the crosslinked microfiber groups ( Fig. 4 B ). 
However, the average melting temperature of all the extruded 
microfibers (74 ± 3 °C) was significantly higher than that for 
the human AT (60 °C) [62] , indicating improved overall structural 
stability [63] . ATR-FTIR spectral analysis ( Fig. 4 C ) showed amide 
I peak at ~1628 cm −1 , amide II peak at ~1542 cm −1 , amide III 
peak at ~1237, amide A peak at ~2944cm −1, and amide B peak 
at ~3298 cm −1 for the untreated and the crosslinked microfibers. 
These values were not significantly different from the starting 
material, indicating that microfibers’ secondary structure was un- 
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Fig. 5. Mechanical stability of Telo GLY microfibers incubated in sterile EMEM and under tension assessed after 1 week, 1 month, 3 months, and six months in a humidified 
incubator at 37 °C and 5% CO 2 show that Telo GLY microfibers at the end of 6 months swell by 50% (A), lost 60% of the Force at Failure (B), 80% of UTS (C) and 80% of 
Modulus (D) compared to Day 0. However, there was no significant change in % Strain at failure at the end of 6 months. All the values depicted in A-E have been normalized 
to a value of 1 for Day 0. The continuous lines in A-E are drawn by inspection only to serve as a guide to the reader. Data are shown as mean ± S.E.M. and are representative 
of at least five replicates. 
3.4. Effect of long-term hydration of microfibers in culture media on 
mechanical properties and degree of swelling 
With Telo GLY microfibers showing optimal mechanical proper- 
ties, this group was further tested for long-term stability mimick- 
ing in vitro physiological conditions. There was no significant dif- 
ference in the Telo GLY fibers’ mechanical properties before and 
after E-beam sterilization (see Section 2.10 ). Incubation in EMEM 
for six months at 37 °C led to an increase (swelling) in microfiber 
width by 53% (36.4 ± 1.1μm on Day 0 to 56.0 ± 1.6 μm at six 
months) as shown in Fig. 5 A . The swelling was accompanied by an 
expected decrease in mechanical properties due to the increase in 
cross-sectional area. However, the mean force at failure decreased 
by only 54% from its initial value in 6 months ( Fig. 5 B ). Mean UTS 
and modulus were reduced by 82% from the starting point in 6 
months ( Fig. 5 C and D ). There was no significant change in the 
strain at break (%) between Day 0 and 6 months of incubation 
( Fig. 5 E). Fig. 5 further shows that Telo GLY microfibers have not 
wholly dissolved when incubated in an in vitro simulated biologi- 
cal environment for up to 6 months. 
3.5. Tenocyte survival and cytotoxicity of the extruded microfibers 
Human tenocytes were used to assess collagen fiber cytocom- 
patibility, which was highly compatible via multiple assays. No sig- 
nificant change in tenocytes’ survival over 7 days was noted by 
AlamarBlue fluorescence ( Fig. 6 A ) compared to the positive con- 
trol (Cells only group). However, survival for cells growing with 
microfibers from selected fiber groups was significantly higher 
(p < 0.05) than that for negative controls (10mM glyoxal chemical 
[neat] and ZDBC film). Tenocytes viability was between 75% and 
85% on glyoxal crosslinked collagen fibers compared to tenocytes 
growing on culture plastic (100%) when assayed using the MTT 
reagent ( Fig. 6 B ). The negative controls (10mM GLY chemical and 
ZDBC film) demonstrated significantly lower (p < 0.005) tenocyte 
survival than the “Cells Only,” Telo DLG, Atelo GLY, and Telo GLY 
groups. Similar results were observed using LDH assay ( Fig. 7 C) 
wherein all the extruded microfiber groups except for Atelo DLG 
and Telo DLG elicited tenocyte viability similar to the “Cells Only”
group. At the end of 7 days, the 10mM GLY chemical group did not 
have enough tenocytes (ND) to be assayed by LDH release into the 
media. We also used a commercially available coated Vicryl suture 
from Ethicon, typically recommended in wound closure, for com- 
parison. Results indicated that our microfibers exhibited signifi- 
cantly lower cytotoxicity (p < 0.005) than the suture using both LDH 
and MTT assays ( Fig. 6 B and C ). Overall, our study used multiple 
assays to establish cytocompatibility of the extruded microfibers. 
The attachment of tenocytes on Telo GLY microfibers with elon- 
gated morphology is shown in Fig. 6 D-E , indicating that the fibers 
imparted alignment along the fibers. 
3.6. Subcutaneous implant biocompatibility and macrophage 
polarization 
All implants appeared macroscopically normal at collection, 
with no notable macroscopic defects at the implant site or nearby 
lymph nodes. Microscopic lesions were also absent in the lymph 
nodes. All implants were microscopically scored using H&E staining 
as having not appreciably degraded. Encapsulation was absent in 
collagen fiber groups (Severity Score average of 1), although encap- 
sulation was moderate to marked in FiberWire TM implants (Sever- 
ity Score average of 3.5). 
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Fig. 6. Effects of crosslinked microfibers on viability, toxicity, and tenocyte attach- 
ment. (A) shows no significant change in survival of human tenocytes incubated 
with the crosslinked microfibers assayed using AlamarBlue after 7 days of incuba- 
tion compared to the cells-only group. Survival was significantly lower in tenocytes 
incubated with negative controls (ZDBC film and 10mM GLY chemical) and vicryl 
suture than the microfiber groups. MTT assay results (C) also revealed a decrease in 
viability for tenocytes incubated with the microfiber groups compared to the cells- 
only group but a significant increase compared to negative controls. On the other 
hand, LDH assay results (D) show a significant decrease in cell survival for the Atelo 
DLG, Telo DLG microfiber groups, and the negative controls. Both MTT and LDH as- 
says were performed at 7 days post-incubation with tenocytes. All data in (B) and 
(C) was normalized to the cells-only group. (ND) indicates that the 10mM Glyoxal 
chemical treatment group had a significant arrest in proliferation resulting in an in- 
sufficient number of cells to detect LDH at the end of the assay timepoint. ( ∗p < 0.05, 
∗∗p < 0.01, ∗∗∗p < 0.0 05 and ∗∗∗∗p < 0.0 0 01). (D) and (E) show representative confocal 
images of human tenocytes attached to Telo GLY microfibers, with DAPI and live- 
cell stain, respectively, showing cytoplasmic extensions and elongated nuclei. 
Scoring inflammatory cells and markers (0 = absent to 4 = se- 
vere) in the collagen fiber implant sites showed little inflammation 
in or around the implants, with a macrophage response proximal 
to the implanted fibers. Collagen fibers were infiltrated with dense 
collagen that was well-integrated with the host tissue, along with 
some neovascularization. FiberWire TM suture implant sites there 
were marked by a foreign body giant cell response, vascularity, 
loose connective tissue and accompanying fat formation around 
the sutures. 
Overall, microscopically, the FiberWire TM suture test article 
caused a pronounced, near three-times higher reaction (reactivity 
score of 19) in the tissue as compared to the mild reaction for col- 
lagen suture crosslinked by glyoxal (reactivity score of 7), and over 
twice the inflammatory reaction or DL-glyceraldehyde crosslinked 
collagen fibers (reactivity score of 10) per Table 2 . 
Immunostaining was used to determine macrophage polariza- 
tion extents in native tissue around microfiber implants from 4 
crosslinker groups. Fig. 7 A and B are representative immunoflu- 
orescent images showing expression patterns of CCR7 (M1) and 
CD163 (M2) macrophage phenotype in the native tissue of rats 
surrounding Telo GLY microfiber implants at four weeks, while 
Fig. 7 C and D show the same for Atelo DLG microfiber implants. 
Fig. 7 E shows quantitation of the percentage of macrophages that 
expressed M1 and M2, M1 only, M2 only, or no M1/M2 pheno- 
type. Glyoxal crosslinked groups (Telo GLY and Atelo GLY) demon- 
strated a significantly higher proportion of macrophages expressing 
M1 and M2 phenotype (~ 40%) compared to the DL-Glyceraldehyde 
crosslinked groups (Telo DLG and Atelo DLG) ( Fig. 7 C ). Further- 
more, between the Telo GLY and Atelo GLY group, Telo GLY im- 
plants elicited a small subset of cells expressing M2 only pheno- 
type (6%), while the rest of the groups had negligible M2 only 
phenotype; Atelo GLY (0.2%), Telo DLG (0%) and Atelo DLG (0%) 
( Fig. 7 E ). There was a significantly higher proportion of cells 
with M1 phenotype in the DL-Glyceraldehyde crosslinked groups; 
Telo DLG (64%) and Atelo DLG (58%) compared to the glyoxal 
crosslinked groups; Telo GLY (24%) and Atelo GLY (19%). Stain- 
ing with appropriate controls revealed negligible non-specific back- 
ground staining (not shown). Sectioning artifacts of the suture con- 
trol samples and significant background staining made it challeng- 
ing to perform this analysis. 
3.7. Development of higher-order structures with collagen microfibers 
With the collagen yarn feedstock manufacturing and glyoxal 
crosslinking optimized at this stage, the ability to form secondary 
or tertiary structures with these collagen filaments using textile 
braiding equipment was explored. Fifty-six collagen fiber strands 
were successfully able to be braided into a 435μm suture (at a 
gauge size of a 4-0 suture per USP < 861 > ), either as a pure col- 
lagen suture or as mixed with polymer strands ( Fig. 8 A and B ). 
Fig. 8 C and D show SEM images of the braid at various resolutions, 
showing high fiber organization and an absence of fiber damage 
from braiding . Fig. 8 E shows an SEM image of a knot with the 
braided collagen suture. Fig. 8 F shows the stress-strain curve after 
mechanically testing the braided suture. The suture exhibits a high 
retained strength post-braiding at over 80 MPa of stress at break 
configured as a pure collagen fiber braid with the initial braiding 
pattern and loading configuration. 
4. Discussion 
We report developing a high output microfluidic extrusion pro- 
cess to manufacture strong, biocompatible type I collagen mi- 
crofibers suitable for surgical suture and possibly other biotex- 
tile manufacturing. This extensive crosslinking study reveals that 
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Table 2 
In Vivo Biocompatibility determined using ISO 10993-6 scoring on H and E stained slides at four weeks 
post-implantation. 
ISO 10993-6 Scoring FiberWire TM Suture Telo GLY Fibers Atelo DLG FIbers 
INFLAMMATIONPolymorphonuclear 1 0 0 
Lymphocytes 0 0 0 
Plasma Cells 1 0 0 
Macrophages 2 2 2 
Giant Cells 2 0 1 
Necrosis 1 0 0 
SUBTOTAL (X2) 14 4 6 
Neovascularization 2 2 2 
Fibrosis 1 1 1 
Fibrotic Encapsulation 2 0 1 
Fatty Infiltrate 0 0 0 
SUBTOTAL 5 3 4 
TOTAL 19 7 10 
Fig. 7. Representative immunofluorescent images showing examples of the host macrophage response to the Telo GLY microfibers (m) (A and B) and Atelo DLG (C and 
D) at four weeks. Arrows indicate examples of cells expressing both M1 and M2 (yellow), M1 only (orange) and M2 only phenotype (white) (Scale bar = 20 μm) CCR7 
(M1) = yellow, CD163 (M2) = red, DAPI (nuclei) = blue. m denotes microfiber bundles. (E) shows the % of cells expressing M1 and M2, M1 only, M2 only, or no M1/M2 
phenotype for the four groups of crosslinked microfibers. Results from this analysis show initiation of pro-regenerative M2 macrophage phenotype in all microfiber groups 
tested. Glyoxal crosslinked fiber groups showed a higher proportion of M1 and M2 phenotype cells than the DL-Glyceraldehyde crosslinked fiber groups. Furthermore, the 
Telo GLY group had a small but significant subset of M2-only macrophages. Expression of CCR7 was used as a marker for M1 and CD163 as a marker for M2. ( ∗p < 0.05, 
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Fig. 8. Braided Collagen Fibers. (A) and (B) show pictures of size 4-0 braided suture using 56 collagen fiber strands. (C) and (D) show representative SEM images of the 
braided suture at two different magnifications. SEM image shows a tight knot tied in the collagen suture (C). Panel (D) shows the stress vs. strain (%) curve for the braid. 
Scale bars: (C) 200μm, (D) 100 μm and (E) 200 μm. 
Table 3 
Mechanical tensile properties (hydrated) of strongest collagen fibers made with different crosslinkers in the literature 
compared to the present study. 
Reference Crosslinker/Crosslinking Method UTS (MPa) Modulus (MPa) Strain at Failure (%) 
Present Study Glyoxal 299 ± 15 3431 ± 86 9.5 ± 1.6 
Yaari et al. [66] Glutaraldehyde 151 ± 31 888 ± 153 20.5 ± 2 
Ahmad et al. [49] EDC a 150 ± 100 1000 ± 600 18 ± 12 
Wang et al. [64] DHT 92 ± 31 895 ± 206 12 ± 2 
Koob et al. [53] NDGA 91 ± 10 696 ± 38 11 ± 1 
a Values were estimated from graphical data published. Exact values were unavailable . 
demonstrate dry and wet-tensile properties superior to prior 
crosslinked collagen extruded microfibers [38 , 39 , 42–44 , 49 , 64–66] 
( Table 3 ). While some previous studies obscured whether tensile 
testing was performed on hydrated or dry fibers or how the fibers 
were wetted if fully hydrated, we show both the dry and hydrated 
properties of our optimized crosslinked fibers with a detailed test- 
ing methodology. 
As crosslinking has been shown to change the mechani- 
cal strength of collagen-based biomaterials [40] , we tested a 
plethora of common and uncommon crosslinkers and crosslink- 
ing conditions ( Table 1 ) encompassing chemical (glyoxal, DL- 
Glyceraldehyde), physical (UVR, DHT), and enzymatic (transglutam- 
inase) techniques. Fig. 1 shows that the UTS and modulus of colla- 
gen microfibers made using our high output microfluidic extrusion 
setup can be varied over 200-fold by selecting a specific crosslink- 
ing condition. 
The changes made to scale-up manufacturing on a grooved 
solid drum led to significant alterations in all the crosslinked mi- 
crofibers’ structural and hydrated mechanical properties ( Figs. 2 
and 3 ). Mechanically, this improved strength may be related to 
tempering, thinning, and improved molecular alignment to rib- 
bons, which were once cylindrical, resulting in fiber tensile proper- 
ties stronger than the human ACL, Achilles tendon, dermis, or any 
other soft connective tissue. Microfibers surface morphology has 
previously been shown to be dependent on crosslinking techniques 
used [39] . Chemical crosslinking of collagen microfibers results in 
dry microfibers with prominent ridges and crevices along the mi- 
crofibers’ longitudinal axis, such as that seen in our case. This type 
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of structural morphology has been shown to facilitate cell attach- 
ment and fibroblast migration [58 , 67] . 
While prior studies focus predominantly on crosslinking strate- 
gies to enhance extruded fibers’ mechanical properties [22 , 42 , 49] , 
emphasis on determining the degree of crosslinking mechanism 
efficiency is lacking. Insufficient crosslinking can lead to lower 
tensile strengths, while chemical crosslinker overuse can lead to 
crosslinker residues on the microfibers’ surface, resulting in cyto- 
toxicity. Here, we performed the ninhydrin assay ( Fig. 4 A) and ob- 
served that groups with maximum crosslinking degrees were those 
that were crosslinked for 72 hours (Telo GLY and Atelo DLG), which 
also correlated with a significant increase in tensile strength. 
The chemistry of crosslinking using aldehydes involves forming 
Schiff’s base type compounds with functional amino groups in col- 
lagen, leading to strong molecular bonds [68] . Chemical analy- 
sis of our extruded microfibers revealed that only the crosslinked 
microfibers (unlike the starting material or the untreated mi- 
crofibers) were resistant to acid hydrolysis. Thus, our microfluidics 
setup generated microfibers with chemical stability higher than the 
lyophilized starting material suggesting tight packing of the colla- 
gen molecules in the microfibers resulting in a stable higher-order 
structure with possibly low internal moisture content. 
The neutralizing formation buffer used in this study contains 
10% PEG (Section 4.1). Molecular crowding, achieved by the addi- 
tion of PEG, during self-assembly of collagen monomers may re- 
sult in more efficient packing and alignment of the fibers [69] . 
Such higher-order structure has been reported in native connec- 
tive tissues [2 , 70] . Limited peptic digestion of the collagen mi- 
crofibers suggests native triple-helical structure preservation post 
extrusion and crosslinking. ATR-FTIR spectral peaks of the starting 
lyophilized material and the extruded fibers presented in Fig. 4 C 
also indicated that neither the extrusion process nor the crosslink- 
ing technique changed collagen structure significantly relative to 
the native collagen starting material, showing native-like collagen 
fibril formation. 
We show proof-of-concept that our optimized collagen mi- 
crofibers, crosslinked with the glyoxal crosslinker by a Maillard re- 
action [71] , can be used in textile-style manufacturing to form a 
braid ( Fig. 6 ). While glyoxal has previously been used to crosslink 
collagen/chitosan composite hydrogels for bone tissue engineering 
[52] , this is the first report to demonstrate glyoxal use to bioengi- 
neer additively manufactured collagen microfiber intended for bio- 
textiles (e.g. bioactive suture or sheets). We produced a continuous 
10 kilometers of clinical grade collagen as fibers without breaks, 
showing promise for large-scale manufacturing of a first-ever colla- 
gen microfiber-based braided suture made with biocompatible gly- 
oxal crosslinking. The resulting braid was pliable, strong, and eas- 
ily tied with a simple surgeon’s knot and could be used with bone 
anchors to internally brace a ligament. The collagen braid UTS ex- 
ceeds that of native ligament and tendon tissues. The collagen su- 
ture exhibited an increased strain at break relative to the individ- 
ual feedstock fibers, as expected by the pure collagen braided su- 
ture’s imparted loose braiding structure in these prototypes. 
Augmenting suture repair of ligaments or tendons with 
collagen-based microfibers or using a collagen-based braided su- 
ture in wound healing requires them to support the tissue me- 
chanically and promote tissue remodeling at a reasonable rate [38] . 
In vitro and in vivo biocompatibility tests are critical to establishing 
these chemically crosslinked microfibers’ effects on cytotoxicity, in- 
flammatory and healing response. Multiple assays indicated that 
our extruded microfiber bundles were cytocompatible, with mini- 
mal toxicity to human tenocytes. Microfluidic extruded microfibers 
further supported human tenocytes’ attachment and assumed the 
elongated shape observed on connective tissue [20] . 
Biocompatibility is defined as the ability of an implant to “lo- 
cally trigger and guide non-fibrotic wound-healing, reconstruction, 
and tissue integration” [72] . Microfiber biocompatibility was exam- 
ined following subcutaneous implantation in rats at four weeks. 
Per ISO 10993 scoring, crosslinked microfiber bundle implants 
exhibited very low (glyoxal groups) to low (DL-glyceraldehyde 
groups) inflammatory response . The glyoxal-telocollagen fiber 
group (Telo GLY) demonstrated a pro-regenerative response. Addi- 
tionally, long-term stability data and rat histology images indicated 
microfiber stability for up to at least 6 months in vitro and 4 weeks 
in vivo . Another important metric for new biomaterial characteri- 
zation is evaluating its hemolytic properties to ensure that it does 
not cause erythrocyte hemolysis. This will be addressed in subse- 
quent studies from our group. 
Macrophages are a heterogeneous mix of mononuclear cells ac- 
tivated in the host due to tissue damage [73 , 74] such as, during 
implantation of materials. Previous studies have highlighted the 
importance of determining macrophage phenotype polarization at 
the implant and host tissue interface [75 , 76] to assess the host’s 
potential to overcome pro-inflammatory signals and transition to- 
wards tissue repair remodeling in response to the surgical implant. 
Macrophage phenotype has been broadly characterized as pro- 
inflammatory M1 macrophages and regenerative M2 macrophages 
with immunoregulatory or tissue remodeling characteristics [77] . 
However, it is essential to note that activated macrophages have 
the plasticity to switch from M1 to M2 and M2 to M1 phenotypes 
easily triggered by changes in the local microenvironment [78 , 79] . 
Due to this, macrophages may also adopt transitional characteris- 
tics of both M1 and M2 phenotype [80] . We determined the pro- 
portion of cells exhibiting M1, M1, and M2 or M2 phenotypes in 
the current study. We thus inferred that at 4 weeks of implanta- 
tion, the glyoxal crosslinking groups had cells with more M1 and 
M2 or M2 only phenotype indicating that the host had initiated 
a tissue remodeling response at 4 weeks. Therefore, we conclude 
that the microfibers from the glyoxal groups were the most bio- 
compatible. To the best of our knowledge, such in-depth analysis of 
immunologic response has not been performed using crosslinked 
collagen microfibers. 
5. Conclusion and clinical significance 
In this study, using clinical-grade commercially available type 
I collagen, we report an advanced microfluidic extrusion process 
for bio-fabricating type I collagen microfibers. Glyoxal crosslinked 
collagen fibers exhibit superior tensile properties, biocompatability 
and manufacturability . Glyoxal, a metabolic byproduct of glycol- 
ysis, is well known to interact with collagen, particularly in con- 
nective tissues. However, this is the first report demonstrating this 
native tissue crosslinker’s extraordinary ability to produce strong, 
cytocompatible, and biocompatible collagen microfibers from mi- 
crofluidic wet-extrusion that are ideally suited for clinical use as a 
biotextile or suture. This high output collagen extrusion approach 
has great potential in advancing tissue repair as a suture, such 
as for ligament and tendon repair or internal bracing in sports 
medicine, for improving cosmesis and lifts in plastic surgery, and 
other surgical indications. 
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